JPMorgan lowered the firm’s price target on AnaptysBio (ANAB) to $66 from $75 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology space.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks